Patent application number | Description | Published |
20120251790 | SYSTEMS AND METHODS FOR CREATING SHARP FEATURES WITHIN A MOLD - The present disclosure describes systems and methods for creating sharp features within a mold. For example, three or more mold plates may be provided to create a single mold assembly. Each mold plate includes one or more mold cavities, each having one or more surfaces. The provided mold plates may be assembled to form the mold assembly having a combined mold cavity between adjacent mold cavities of the mold plates. Although none of the individual mold cavities of the mold plates include sharp features, when the mold assembly is assembled, a combined mold cavity will include sharp transitions (e.g., angles of less than 180 degrees, right angles, angles of less than 90 degrees, and so forth) between adjacent surfaces of the mold cavities. In certain embodiments, sets of mold plates may be re-aligned to create varying mold cavity geometries. In addition, in certain embodiments, a mold pin may be inserted into an inner volume of a mold plate to both create additional sharp transitions between adjacent surfaces. | 10-04-2012 |
20120253163 | METHOD AND SYSTEM FOR POSITIONING A SENSOR - Embodiments of the present disclosure relate to sensor designs or shapes configured to facilitate placement of sensor electrodes and, thus, proper positioning of the sensors on patients. According to certain embodiments, a sensor may include a substrate that includes multiple electrodes, where a first electrode is configured to be placed on a patient's temple and a second electrode is configured to be placed on a patient's forehead directly above a patient's eyebrow. The sensor may include a particular shape and a fixed distance between the first and second electrodes to facilitate proper angling and positioning of the first and second electrodes as well as the other electrodes (e.g., third and fourth electrodes). Other embodiments may include a method for positioning the sensor on the patient, including a monitor with help screens. | 10-04-2012 |
20130023748 | DEVICE WITH ENCAPSULATED GEL - Apparatus and techniques are provided for interfacing a device with a surface. The apparatus and techniques provide gel encapsulation and isolation mechanisms to extend the shelf-life of the preparation devices, allow for the use of more effective materials, and improve the quality of the contact between a device and an application surface. Particular embodiments of these apparatus and techniques suitable for use in medical contexts are also provided. | 01-24-2013 |
20130023749 | FORCE REGULATING DEVICE APPLICATORS - Disclosed herein are apparatus and techniques for applying a device to a subject. Such apparatus and techniques may provide feedback to an operator and/or regulate the force used to apply the device, yielding an improved result. Particularly useful embodiments include apparatus and techniques for applying a medical device, such as a skin surface electrode or microneedle array, to a patient's tissue. | 01-24-2013 |
Patent application number | Description | Published |
20090176839 | FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID - The present invention relates to formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, pharmaceutical packs or kits thereof, and methods of treatment therewith. | 07-09-2009 |
20100074949 | Pharmaceutical composition and administration thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 03-25-2010 |
20100087490 | Dosage Units of 3-(6-(1-(2,2-Difluorobenzo[D] [1,3] Dioxol-5-YL) Cyclopropanecarboxamido)-3-Methylpyridin-2-YL)Benzoic Acid - The present invention relates to formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in Form I, pharmaceutical packs or kits thereof, and methods of treatment therewith. | 04-08-2010 |
20110256220 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 10-20-2011 |
20140023706 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 01-23-2014 |
20140112988 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 04-24-2014 |
Patent application number | Description | Published |
20100069434 | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein. | 03-18-2010 |
20110064811 | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 03-17-2011 |
20120122922 | COMPOSITIONS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE- -3-CARBOXAMIDE - Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein. | 05-17-2012 |
20120214841 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE- -3-CARBOXAMIDE - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 08-23-2012 |
20120220625 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 08-30-2012 |
20120258983 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 10-11-2012 |
20130317060 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N—[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 11-28-2013 |
20140242172 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 08-28-2014 |
20140315948 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 10-23-2014 |
Patent application number | Description | Published |
20100137696 | MEDICAL DEVICE WITH RESERVOIR-BASED SENSORS - A medical device is provided which may include a reservoir which has an opening and contains a sensor; a reservoir cap closing off the opening to isolate the sensor from an environmental component outside the reservoirs, the reservoir cap being impermeable to the environmental component and adapted to selectively undergo a phase change to disintegrate the reservoir cap and thereby expose the sensor to the environmental component. A method of use may include (i) selectively disintegrating a reservoir cap to expose a sensor which is disposed inside a reservoir of a device implanted in a patient, the disintegrating comprising inducing a phase change in the reservoir cap; and (ii) using the sensor to generate an output signal, wherein the output signal is recorded and stored in a writeable computer memory chips, directed to a microprocessor for immediate analysis and processing, or sent to a remote location away from the device. | 06-03-2010 |
20100224488 | Bilirubin Sensor - A bilirubin sensor has a working electrode with a first chemical matrix disposed thereon that contains a binder, a substrate electrode with a second chemical matrix dispose thereon that contains a binder and a chemical agent that consumes bilirubin, a reference electrode, a sample chamber containing the working electrode, the substrate electrode and the reference electrode, and a method of measuring bilirubin in a body fluid. | 09-09-2010 |
20100270175 | Electrochemical biosensors based on NAD(P)-dependent dehydrogenase enzymes - A biosensor for measuring an analyte in a liquid sample includes a working electrode having a dispensed reagent thereon wherein the dispensed reagent contains an enzyme capable of catalyzing a reaction involving the analyte, a mediator that is considered an enzyme inhibitor, and an enzyme co-factor where the working electrode provides a stable and sensitive response even when the biosensor is stored at ambient conditions for a period of time selected from the group consisting of at least 3 months, 12 months and two years or. | 10-28-2010 |
20130062221 | DISPOSABLE SENSOR FOR ELECTROCHEMICAL DETECTION OF HEMOGLOBIN - A disposable biosensor for determining the content of hemoglobin and hematocrit in a sample of whole blood that includes a laminated strip with a first and second end, at least a reference, a working electrode and a blank electrode embedded in the laminated strip. The working electrode contains a reagent sensitive to hemoglobin or hemotocrit. The blank electrode is used to measure oxidizable species in the fluid sample and to correct the current signal of the working electrode. The construction of the biosensor allows accurate measurement of the impedance of a small fluid sample, which is used to further correct the current signal of the working electrode. | 03-14-2013 |
20130098775 | Glucose biosensor with improved shelf life - A disposable biosensor having improved long term storage stability including a working electrode and a reference electrode formed on an insulating substrate and a dissolvable reagent layer composition disposed directly on the working electrode where the reagent layer composition contains a glucose-based enzyme, a reagent component selected from a phosphate buffer and a tris reagent, and a redox mediator. | 04-25-2013 |
20140069823 | Disposable urea sensor and system for determining creatinine and urea nitrogen-to-creatinine ratio in a single device - A disposable urea sensor has a laminated body having a fluid sample inlet end and an electrical contact end, a fluid sample inlet, a substantially flat sample chamber in communication between the fluid sample inlet and a vent opening, the sample chamber being adapted to collect a fluid sample through the fluid sample inlet, a working electrode and a reference electrode within the sample chamber, and a reagent matrix disposed on the working electrode wherein the reagent matrix contains urease. | 03-13-2014 |
20150021205 | Sampling method and system for measuring blood lactate concentrations - A method of measuring lactate in a blood sample taken from capillary blood using a skin lancing procedure includes disposing onto an area of skin on an animal a predefined amount of a skin treatment compound that is capable of suppressing and/or eliminating and/or preventing and/or blocking any sweat from the skin in the area of a lanced wound site, the compound being disposed on the skin either before lancing the area of skin that provides a droplet of capillary blood for measurement of blood lactate concentration or after lancing the area of skin but before a droplet of capillary blood forms on the skin in order to prevent contaminating the blood sample, and then measuring the lactate concentration of the blood sample with a disposable lactate sensor strip. | 01-22-2015 |
Patent application number | Description | Published |
20120302505 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. | 11-29-2012 |
20130210724 | Cyclodextrin-Based Polymers for Therapeutic Delivery - Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. | 08-15-2013 |
20140213504 | Cyclodextrin-Based Polymers for Therapeutic Delivery - Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. | 07-31-2014 |
Patent application number | Description | Published |
20080241098 | ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY - Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE). | 10-02-2008 |
20090298081 | METHODS OF TREATMENT UTILIZING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR - The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders. | 12-03-2009 |
20090298167 | INTERLEUKIN-21 RECEPTOR BINDING PROTEINS - The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders. | 12-03-2009 |
20100297151 | ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders. | 11-25-2010 |
20110142833 | METHODS FOR TREATING AND PREVENTING FIBROSIS - The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R). | 06-16-2011 |
20120264919 | INTERLEUKIN-21 RECEPTOR BINDING PROTEINS - The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders. | 10-18-2012 |
20120276102 | METHODS OF TREATMENT UTILIZIING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR - The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders. | 11-01-2012 |
Patent application number | Description | Published |
20090131423 | Tyrosine Kinase Inhibitors - The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 05-21-2009 |
20090197908 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met - The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 08-06-2009 |
20090306071 | Inhibitors of Janus Kinases - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 12-10-2009 |
20100048551 | Tricyclic Compounds Useful as Inhibitors of Kinases - The present invention provides inhibitors of kinases, specifically IκB kinases, JAK1, JAK2, JAK3 and TYK2. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting said kinase activity by administering the compound to a patient in need of treatment for myeloproliferative disorders, cancer or NF-κB-mediated diseases. | 02-25-2010 |
20100267709 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 10-21-2010 |
20140235641 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS - The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer. | 08-21-2014 |
Patent application number | Description | Published |
20100049232 | COLLAPSIBLE LANCING DEVICE - A lancing device for use with a removable lancet having a sharp tip. The lancet includes a housing. The lancing device can include a handle connected to the housing for movement between a storage position, where the housing and handle are configured to be compactly stowed, and a use position, where the housing and handle are configured to be grasped by a user to perform the piercing operation. The lancing device can include an opening formed in the housing and a tray that is moveable with respect to the housing between an open position, where the lancet can be installed on or removed from the tray, and a closed position, where the lancet can be utilized to perform a piercing operation. The lancing device can include a structure moveable with respect to the housing between a first position, where a first piercing aperture is defined, and a second position, where a second piercing aperture is defined, where the second piercing aperture is larger than the first piercing aperture. | 02-25-2010 |
20100049233 | LANCET HAVING INTEGRATED DRIVE MECHANISM - A lancet for use with a lancing device is provided. The lancet includes a lancet body and a drive mechanism attached to the lancet body. A needle projects from an end of the lancet body. The drive mechanism is operative in response to insertion of the lancet in the lancing device to bias the lancet toward a pricking position. | 02-25-2010 |
20120022565 | COLLAPSIBLE LANCING DEVICE - Disclosed herein are embodiments of lancing devices for use with a lancet having a lancet body and a sharp tip covered by a removable cap. One lancing device comprises a housing having a first end and a second end opposite the first end, a drawer received within the housing at the first end and movable between an open position and a closed position, the drawer having a drawer face and a drawer body, the drawer body configured to receive the lancet, and a decapping arm disposed within the housing and connected to the housing via a pivot at the second end of the housing, the decapping arm movable about the pivot between a storage position and a decapping position. | 01-26-2012 |
Patent application number | Description | Published |
20080213893 | ISOLATION OF NEURAL STEM CELLS USING GANGLIOSIDES AND OTHER SURFACE MARKERS - During the growth and study of NSCs, a range of molecules present on the surface of multipotent neural stem and progenitor cells (NSCs) were identified. These markers were identified using a number of human and murine neural stem cell lines, including retinal stem cells (RSCs). The NSC-specific markers identified included gene products as well as non-protein molecules and sugar epitopes not directly coded in the genome. Together with surface markers which were determined to be absent from the surface of hNSCs, the molecules described herein provide a means to enrich for neural stem cells, or neural progenitor subpopulations, particularly using combinatorial cell sorting strategies. These same molecules also represent targets for pharmacological manipulation of NSC populations and subpopulations, both in vivo and ex vivo. Furthermore, these molecules provide potential targets for therapeutic manipulation of other neural precursor-related cell types including malignant conditions as well as other diseases originating from, or preferentially affecting, various uncommitted or replication-competent cell types. | 09-04-2008 |
20090104694 | ISOLATION AND TRANSPLANTATION OF RETINAL STEM CELLS - The present invention relates to the isolation, in vitro propagation, and transplantation and integration of non-pigmented retinal stem cells derived from the neuroretina of the eye, ex vivo and in vivo. | 04-23-2009 |
20120321593 | LOW OXYGEN CULTURE CONDITIONS FOR MAINTAINING RETINAL PROGENITOR CELL MULTIPOTENCY - The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration. | 12-20-2012 |
20130189341 | GENERATION OF PHOTORECEPTORS FROM HUMAN RETINAL PROGENITOR CELLS USING POLYCAPROLACTONE SUBSTRATES - The present invention relates to biocompatible compositions for transplantation into a sub-retinal space of the human eye. The compositions include a biodegradable polyester film, preferably a polycaprolactone (PCL) film, and a layer of human retinal progenitor cells. The compositions of the invention can be used as scaffolds for the treatment a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration. | 07-25-2013 |
20140140965 | LOW OXYGEN CULTURE CONDITIONS FOR MAINTAINING RETINAL PROGENITOR CELL MULTIPOTENCY - The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration. | 05-22-2014 |
20150017133 | PHENOTYPE PROFILE OF HUMAN RETINAL PROGENITOR CELLS - The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogeneous cell populations from human tissue using cell sorting techniques. | 01-15-2015 |
20150030658 | GENERATION OF PHOTORECEPTORS FROM HUMAN RETINAL PROGENITOR CELLS USING POLYCAPROLACTONE SUBSTRATES - The present invention relates to biocompatible compositions for transplantation into a sub-retinal space of the human eye. The compositions include a biodegradable polyester film, preferably a polycaprolactone (PCL) film, and a layer of human retinal progenitor cells. The compositions of the invention can be used as scaffolds for the treatment a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration. | 01-29-2015 |
Patent application number | Description | Published |
20090042792 | 18 HUMAN SECRETED PROTEINS - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 02-12-2009 |
20090311256 | 12 Human Secreted Proteins - The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. | 12-17-2009 |
20110003383 | ANTIBODIES TO HT5GJ57 - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 01-06-2011 |
20110178066 | Hydroxypiperidine derivatives and uses thereof - Chemical agents, such as derivatives of hydroxypiperidine moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents. | 07-21-2011 |
20120122762 | 186 Human Secreted Proteins - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 05-17-2012 |
Patent application number | Description | Published |
20080241822 | GENOME-WIDE LOCATION AND FUNCTION OF DNA BINDING PROTEINS - The present invention relates to a method of identifying a region (one or more) of a genome of a cell to which a protein of interest binds. In the methods described herein, DNA binding protein of a cell is linked (e.g., covalently crosslinked) to genomic DNA of a cell. The genomic DNA to which the DNA binding protein is linked is removed and combined or contacted with DNA comprising a sequence complementary to genomic DNA of the cell under conditions in which hybridization between the identified genomic DNA and the sequence complementary to genomic DNA occurs. Region(s) of hybridization are region(s) of the genome of the cell to which the protein of binds. A method of identifying a set of genes where cell cycle regulator binding correlates with gene expression and of identifying genomic targets of cell cycle transcription activators in living cells is also encompassed. | 10-02-2008 |
20090143240 | Novel Methods for Genome-Wide Location Analysis - The invention relates to improved methods of identifying the genomic regions to which a protein of interest binds, and in particular, to methods that use tiled arrays. The invention also provides methods of identifying the transcriptional rate of the gene in a cell. The invention also relates to methods of performing genome-wide location analysis, and ChIP-CHIP analysis, using histones and modified histones. | 06-04-2009 |
20090221428 | Methods of Genome-Wide Location Analysis in Stem Cells - The invention relates to improved methods of identifying the genomic regions to which a protein of interest binds, and in particular, to methods that apply to stem cells such as but not limited to; embryonic stem cells and adult stem cells. The invention also provides methods of identifying agents which modulate differentiation of stem cells. The invention also provides methods of defining the differentiation potential of a cell and of designing array oligonucleotides. | 09-03-2009 |
20100040645 | IN VIVO CTL ELICITATION BY HEAT SHOCK PROTEIN FUSION PROTEINS MAPS TO A DISCRETE DOMAIN AND IS CD4+ T CELL-INDEPENDENT - The present invention relates to a method of inducing a CD8 | 02-18-2010 |
20100310525 | WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC CELLS - The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway. | 12-09-2010 |
20120034192 | COMPOSITIONS AND METHODS FOR ENHANCING CELL REPROGRAMMING - The invention provides compositions and methods of use to enhance reprogramming of mammalian cells. Certain compositions and methods of the invention are of use to enhance generation of induced pluripotent stem cells by reprogramming somatic cells. Certain compositions and methods of the invention are of use to enhance reprogramming of pluripotent mammalian cells to a differentiated cell type. Certain compositions and methods of the invention are of use to enhance reprogramming of differentiated mammalian cells of a first cell type to differentiated mammalian cells of a second differentiated cell type. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that enhances or contributes to reprogramming mammalian cells. Certain of the inventive compositions and methods relate to inhibiting histone methylation. | 02-09-2012 |
20130053415 | COMBINATION METHODS FOR TREATMENT OF DISEASE - In some aspects, the invention provides compositions and methods of use for treating a variety of diseases. In some aspect, the compositions and methods involve combined modulation of transcriptional modulators. | 02-28-2013 |
20130109737 | MEDIATOR AND COHESIN CONNECT GENE EXPRESSION AND CHROMATIN ARCHITECTURE | 05-02-2013 |
20140287932 | SUPER-ENHANCERS AND METHODS OF USE THEREOF - The present invention relates in some aspects to super-enhancers and related compositions, methods, and agents that are useful for modulating expression of cell type-specific genes that are required for maintenance of cell identity (e.g., embryonic stem cell identity) or maintenance of a disease state (e.g., cancer). | 09-25-2014 |
20140296218 | SUPER-ENHANCERS AND METHODS OF USE THEREOF - The present invention relates in some aspects to super-enhancers and related compositions, methods, and agents that are useful for modulating expression of cell type-specific genes that are required for maintenance of cell identity (e.g., embryonic stem cell identity) or maintenance of a disease state (e.g., cancer). | 10-02-2014 |